Evaluating Low-Intensity Extracorporeal Shockwave Therapy Combined with PDE5 Inhibitors for Penile Rehabilitation After Robot-Assisted Surgery for Genitourinary Cancers
Led by Regina Elena Cancer Institute · Updated on 2026-08-14
158
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of Low-intensity Extracorporeal Shock Wave Therapy Li-ESWT combined with PDE5 inhibitors PDE5i compared to PDE5i alone for treating erectile dysfunction ED after robot-assisted radical prostatectomy RARP in men with prostate cancer. This phase 3 randomized controlled trial aims to provide strong evidence on whether early penile rehabilitation using Li-ESWT plus PDE5i leads to faster and better recovery of erections as measured by the International Index of Erectile Function-5 IIEF-5.
Participants are randomly assigned to two groups one receives Li-ESWT plus daily tadalafil 5 mg started shortly after catheter removal, and the other receives tadalafil alone. Li-ESWT is administered using a device delivering 12,000 shockwaves in a single session weekly for six weeks, targeting the erectile tissue with precise energy dosing. Both groups continue PDE5i treatment for one year, with assessments at 3, 6, and 12 months post-surgery.
Participants will be monitored for erectile function using IIEF-5 and Erectile Hardness Score EHS, urinary continence, adverse effects, and health-related quality of life via questionnaires. PSA levels are measured 45 days after surgery to confirm eligibility. After one year, a two-week washout without PDE5i occurs to evaluate erectile function without medication. Data on safety, sexual recovery, and quality of life will be collected over the study period, which lasts up to one year after treatment.
CONDITIONS
Brief Title
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
Research Team
G
Giuseppe Simone
R
Riccardo Mastroianni
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Preoperative International Index of Erectile Function-5 (IIEF-5) score of 17 or higher
First PSA measurement 45 days after surgery less than 0.1
Final pathology prostate cancer ISUP grade 2 or lower and pathological stage less than pT3b
Able and willing to comply with study protocol and complete questionnaires
Able to provide written informed consent
You will not qualify if you...
Contraindications to robotic surgery anesthesia
Previous pelvic radiotherapy or androgen deprivation therapy
Major postoperative complications classified as Clavien-Dindo 3 or higher
Cardiovascular contraindications to PDE5 inhibitor treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial PSA test 45 days after surgery before randomization
Treatment
Duration - Up to 1 year
Participants receive either Li-ESWT plus daily PDE5 inhibitors or PDE5 inhibitors alone for penile rehabilitation after surgery.
Weekly visits for the first 6 weeks during Li-ESWT sessions, then regular follow-up visits at 3, 6, and 12 months
Washout and Follow-up
Duration - Approximately 2 weeks plus ongoing follow-up
After one year of treatment, participants stop PDE5 inhibitors for two weeks to assess erectile function without medication, followed by continued monitoring.
Assessment visits to collect erectile function scores post-washout
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Exploring the Distribution of 99mTc-PSMA-I&S in Men Undergoing Surgery for Prostate Cancer
Using Imaging and Histopathology for Validation
Evaluating a Virtual Reality Assistant to Support Newly Diagnosed Black Men with Prostate Cancer
Using an Online Platform to Help Adults with Lung, Colorectal, Breast, or Prostate Cancer Track Medication Safety at Home
Phase 2 Study of ST-04 Intraurethral Alprostadil Paste for Treating Erectile Dysfunction in Adult Men
Phase II Study of 18F-rhPSMA-7.3 PET-mpMRI Imaging to Improve Detection of Prostate Cancer and Guide Targeted Biopsy Using TRUS-MR Fusion
Evaluating Flotufolastat F 18 PETCT Imaging to Detect Prostate Cancer After Focal Therapy
Study of Hormone Therapy With or Without Niraparib After Radiation in High-Risk Localized or Locally Advanced Prostate Cancer
Respiratory Training to Improve Brain and Mental Health in Adults with Cancer, Multiple Sclerosis, and Their Caregivers
Study of Bright White Light Therapy During Antiandrogen Combination Treatment in Men with Advanced Prostate Cancer to Support Physical and Mental Health
Building Community Living Labs to Improve Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men at American Legion Posts
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities.
Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial.
Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.